CC
INDP icon

Caxton Corporation’s Indaptus Therapeutics INDP Stock Holding History

Caxton Corporation’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19
Closed -$318K – 29
2018
Q4 		$318K Sell
19
-10
-34% -$136K 0.39% 18
2018
Q3 		$364K Hold
29
– – 0.34% 19
2018
Q2 		$285K Hold
29
– – 0.1% 19
2018
Q1 		$395K Sell
29
-3
-9% -$42.5K 0.43% 16
2017
Q4 		$375K Sell
32
-2
-6% -$31K 0.46% 15
2017
Q3 		$681K Buy
+34
New +$490K 0.69% 9

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Caxton Corporation's INDP Position: Q1 2019 in Review

Caxton Corporation sold out of Indaptus Therapeutics (INDP) in Q1 2019, closing a stake of 19 shares — an estimated $318K sold.

Caxton Corporation first reported a position in INDP in Q3 2017 and held it in 6 quarters. The position peaked at $681K in Q3 2017. 36 funds tracked by Wall St. Rank hold INDP as of Q1 2019.

  • Caxton Corporation reported no remaining Indaptus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Caxton Corporation sold 19 Indaptus Therapeutics shares in Q1 2019, an estimated $318K.
  • Caxton Corporation first reported a position in Indaptus Therapeutics in Q3 2017 and held it in 6 quarters.
  • Caxton Corporation's Indaptus Therapeutics position peaked at $681K in Q3 2017.
  • 36 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2019.

Based on Caxton Corporation's 13F filing for Q1 2019, filed 14 May 2019.